Differentiated Influenza A/B
and RSV testing
is here


Fast results when answers matter most

The young and old are particularly vulnerable to infection from respiratory syncytial virus (RSV). It is the leading cause of lower respiratory disease for children younger than 4 years, and globally, nearly all children are infected by age two.1  On the other side of the age continuum, RSV is also common in adults older than 65 and their risk of serious infection increases with age.2 Timely results from cobas® Influenza A/B & RSV help guide clinical response for infection management and control. Performance of the cobas® Influenza A/B & RSV test was compared with an FDA-cleared, laboratory-based, multiplexed, real-time, reverse transcription PCR (RT-PCR) test across three targets:

cobas® Influenza A/B & RSV performance


The cobas® Liat® PCR System vs. Conventional methods

Influenza A/B rapid antigen test
(Test 1 of 2)


RSV rapid antigen test
(Test 2 of 2)


cobas® Influenza A/B & RSV
(3 targets in 1 test)



Intended use for cobas® Influenza A/B & RSV3

The cobas® Influenza A/B & RSV Nucleic acid test, for use on the cobas® Liat® System, is an automated multiplex real-time RT-PCR assay for the rapid in vitro qualitative detection and discrimination of Influenza A virus, Influenza B virus, and respiratory syncytial virus RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors.
The test is intended for use as an aid in the differential diagnosis of Influenza A, Influenza B, and RSV in humans and is not intended to detect Influenza C.
CE-IVD and 510 (k) cleared; CLIA waived. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.


Learn more about the expanding menus of assays.

*RIDT=rapid influenza diagnostic test.
**RADT=rapid antigen diagnostic test.

References: 1. Collins PL and Grahm BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 2008:82(5);2040-2055. 2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults.  NEJM. 2005:352(17);1749-59. 3. cobas® Influenza A/B & RSV [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 4. Centers for Disease Control and Prevention. Use of antivirals. http://www.cdc.gov/flu/professionals/antivirals/antiviral-use-influenza.htm. Accessed April 20, 2017